Determining optimal combination regimens for patients with multiple myeloma

Mahya Aghaee, Urszula Ledzewicz, Michael Robbins, Natalie Bezman, Hearn Jay Cho, Helen Moore

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


While many novel therapies have been approved in recent years for treating patients with multiple myeloma, there is still no established curative regimen, especially for patients with high-risk disease. In this work, we use a mathematical modeling approach to determine combination therapy regimens that maximize healthy lifespan for patients with multiple myeloma. We start with a mathematical model for the underlying disease and immune dynamics, which was presented and analyzed previously. We add the effects of three therapies to the model: pomalidomide, dexamethasone, and elotuzumab. We consider multiple approaches to optimizing combinations of these therapies. We find that optimal control combined with approximation outperforms other methods, in that it can quickly produce a combination regimen that is clinically-feasible and near-optimal. Implications of this work can be used to optimize doses and advance the scheduling of drugs.

Original languageEnglish
Article number106492
JournalEuropean Journal of Pharmaceutical Sciences
StatePublished - 1 Aug 2023


  • Combination drug regimen
  • Constrained optimization
  • Mathematical model
  • Multiple myeloma
  • Optimal control


Dive into the research topics of 'Determining optimal combination regimens for patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this